Search
News & Events
Diabete$ Re$earch in Au$traliaIt may surprise you to know that the Australian government has invested almost $300 million dollars since 2000 towards research and clinical trials for diabetes
News & Events
Low Carbohydrate DietsCarbohydrate restriction is used by some individuals with type 1 diabetes to reduce glucose excursions after eating a meal.
News & Events
Recruitment for AdDIT now completeYoung people diagnosed with Type 1 Diabetes are at risk of complications from their diabetes including kidney, heart, eye and vascular disease.
News & Events
WA teenager with type 1 diabetes on a mission to become a pro-cyclistA wiry tall teenager, who was struggling somewhat with his blood glucose control, he turned up on his trusty bike, and we had something in common to talk about.
T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.
The Rio Tinto Children's Diabetes Centre is a research centre that aims to improve the lives of children and young adults living with diabetes by bringing together research, education and clinical care.
Type 1 diabetes is a chronic autoimmune disease that results from the immune system attacking the insulin-producing cells of the pancreas. Unlike type 2 diabetes which is potentially preventable, type 1 is a non-preventable disease - currently, its exact cause is not known and there is no cure.
Read about the Research Focus Area Leads at the Children's Diabetes Centre.
Many of the Centre's researchers have been responsible for discovering and contributing to real game-changers, making a difference to children with diabetes.
Research
Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetesLess than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.